explemed rapid orodispersible tablet 10mg - Meklēšanas rezultāti

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

pulmoris ambrisentan 10 mg tablet blister pack

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

venlafaxine- venlafaxine hydrochloride tablet, extended release for oral use

osmotica pharmaceutical corp. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - tablet, extended release - 37.5 mg - venlafaxine extended release tablets (venlafaxine hydrochloride) are indicated for the treatment of major depressive disorder (mdd). efficacy of venlafaxine in mdd was shown in both short-term trials and a longer-term trial in mdd [see clinical studies (14.1) ]. a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. venlafaxine extended release tablets are indicated for the treatment of social an

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

artige methylphenidate hydrochloride 10mg tablet blister pack

novartis pharmaceuticals australia pty ltd - methylphenidate hydrochloride, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; calcium phosphate; purified talc; lactose monohydrate; wheat starch; gelatin - treatment of attention-deficit hyperactivity disorder (adhd). treatment of narcolepsy.